DPHARMA | DUOPHARMA BIOTECH BHD*
3.87 (-1.02%)
T-O: 3.92 (08:59:00)
Last updated: 17:00
Fundamental
iSaham Fundamental Trend
FCON: 0.63 | Sharpe Ratio: 0.85 | LTS: 8.32
Quarter Reports
Trailing Dividend
Financial Ratios
| EPS | 8.09 sen |
| Trailing PE (Sector Median: 25.9) | 46.4 |
| PEG | -7.19 |
| Altman Z | 1.3 |
| Beaver | 0.092 |
| Current Ratio | 1.83 |
| Debt-Equity (DE) Ratio | 0.73 |
| FCF Yield | 0.45 % |
| Dividend Per Share (DPS) | 5.5 sen |
| Revenue QoQ | -1.47 % |
| Revenue YoY | 8.44 % |
| Profit QoQ | 5.84 % |
| Profit YoY | 0.27 % |
| NTA QoQ | 11.84 % |
| Profit Margin (Sector Median: 3.3) | 9.47 % |
| ROE | 9.45 % |
| ROIC | 7.57 % |
| Dividend Yield (DY) | 1.42 % |
Fair Value
Weighted Average Fair Value: 2.12
| Discounted Cash Flow (DCF) 5% Growth | 0.775 |
| Discounted Cash Flow (DCF) 10% Growth | 1.02 |
| Relative Valuation | 2.16 |
| Average Analysts FV based on 1 rating(s) | 2.07 |
| Graham Formula | 0.61 |
| Graham Number | 1.27 |
| Net Tangible Asset (NTA) | 0.85 |
Advanced Calculators
Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.
| Growth/Risk Fair Value Calculator | |
| Expected growth (%) | |
| Estimated downside / risk (%) | |
| Estimated New DCF Fair Value |
| Contract/Award Contribution Calculator | |
| Contract/Award Value (in Million) | |
| Estimated Contribution to Stock Price | |
| Estimated New DCF Fair Value |
| Profit-Based Calculator | |
| Expected Profit (M) | |
| for Year | |
| Estimated New DCF Fair Value |
| Revenue-Based Calculator | |
| Expected Revenue (M) | |
| for Year | |
| Estimated New DCF Fair Value |
| Market Pricing | |
| Expected Profit (M) | 620.45 |
| Expected Revenue (M) | 6551.69 |
| Expected Growth (%) | 38.0 |
Directors Share Purchases (Beta)
No transaction in the last 2 months.
Technical
Summary
Market Cap: 2558 M.
Number of Shares: 661 M.
Float: 40.43%.
Stock highly correlated with
APPASIA (95%)
FBMACE (95%)
FOCUS (94%)
JCY (93%)
Manipulation Indicator: Very hard to manipulate.
Duopharma Biotech Group was incorporated in 2000 and is today one of Malaysia’s leading pharmaceutical companies listed on the Main Market of Bursa Malaysia Berhad. Duopharma Biotech has core competencies in the pharmaceutical industry inclusive of Manufacturing, Research & Development and Commercialisation & Marketing of over 300 generic drugs such as Omesec and Prelica as well as Consumer Healthcare (“CHC”) products. The Company has also diversified into the biosimilars space with technology and commercialisation collaborations with credible and strong international partners. Headquartered in Kuala Lumpur, Malaysia, Duopharma Biotech owns and operates three manufacturing plants in Klang, Bangi and Glenmarie, Selangor. Duopharma Biotech also has subsidiary companies in the Philippines and Singapore. A subsidiary of Duopharma Biotech Berhad has a representative office in Jakarta, Indonesia.
Sectors: Consumer Products, Healthcare, Pharmaceuticals, Technology
Code: 7148
Website: http://duopharmabiotech.com/
Related Links: Bursa | Annual Report | Announcement
AGM Doorgift: Pharmacy Products + RM10 TnG (2019) | AGM Announcement
Top Shareholdings
Updated on 25-Mar-2020
| Shareholder | Value (M) |
|---|---|
| Permodalan Nasional Berhad | 1228.81 |
| Employees Provident Fund Board | 221.17 |
| Amanah Saham Bumiputera | 116.1 |
| Billion Victory Sdn Bhd | 66.1 |
| Public Islamic Treasures Growth Fund | 27.9 |
| Norges Bank | 26.3 |
| Manulife Investment Shariah Progressfund | 26.11 |
| Kumpulan Wang Persaraan (Diperbadankan) | 19.77 |
| Principal Dali Opportunities Fund | 17.88 |
| Eastspring Investmentssmall-Cap Fund | 16.23 |
| Manulife Investment Progress Fund | 16.23 |
| Lembaga Tabung Haji | 15.56 |
| Affin Hwang Aiiman Asia (Ex Japan) Growth Fund | 13.02 |
| Amanah Saham Malaysia 3 | 12.05 |
| Tokio Marine Life Insurance Malaysia Bhd | 10.96 |
| Principal Islamic Small Cap Opportunities Fund | 10.57 |
| Affin Hwang Growth Fund | 9.42 |
| Ooi Keng Tan | 8.54 |
| CIMB-Principal Small Cap Fund | 8.3 |
| Petroliam Nasional Berhad | 8.16 |
| Gibraltar BSN Aggressive Fund | 7.69 |
| Affin Hwang Principled Growth Fund | 7.65 |
| Medical Fund | 7.17 |
| Credit Suisse | 7.16 |
| Amtotal Return | 6.83 |
| Hong Leong Assurance Berhad | 6.67 |
| Areca Equitytrust Fund | 6.38 |